All the Active Ingredient Drugs
Anthracycline. Epirubicin HCl 2 mg/ml. VIALS: 1 x 10 mg/5ml; 1 x 50 mg/25 ml, 1
x 100 mg/50 ml. I.V./intravesical use:
Adjust accord. indicat., age, gen. cond.,
card./hepat. funct., concurr.
chemother., blood counts. See lit.
Tmt. wide spectrum neoplast. dis., incl:
breast, lung (high doses), ovarian, gastric,
soft tissue, intravesical admin. for fic.
bladder carcinomas and in proph. recur.
transurethral resect. I.V. admin: Advanced
bladder carcinoma.
C/I: Hypersens. to epirubicin, other
anthracyclines/anthracenediones, bone
marrow depress., pre/exist./acute card.
insuffic., buccal ulcerat., pregn., lact.
See lit.
Anthracycline. Epirubicin HCl 2 mg/ml. VIALS (sol. for inject.): 5 x 5 ml, 10 ml, 25
ml, 50 ml, 100 ml. I.V./intravesical:
Adjust accord. indicat., age, gen. cond., card/hepat. funct., concurr.
chemother., blood counts. See lit.
Tmt. wide spectrum neoplast. dis., incl.
breast carc., lung carc. high doses, ovarian
carc., gastric carc., soft tissue sarcoma.
Intravesical admin. found benefic. tmt. fic.
bladder carc., prophylax. recurr. aft.
transurethral resect. I.V. admin tmt.
advanced bladder carc.
C/I: By I.V. route: Known hypersens.
Severe bone marrow depress. follow.
prev. chemother./ radiother. Pts already
treated with anthracyclines such as
doxorubicin/ daunorubicin up to
relevant max. cumulative dose. Acute
infects., existing inflamm. of buccal/GI
mucosa. Progress. heart fail., arrhythm.,
conduct. disords. with serious
hemodynam. effects, acute inflamm.
myocard. conds., unstable ang. pect.,
acute MI/within 6 mths, cardiomyopath.
By intravesical route: Tmt. of invasive
tumors penetrating bladder wall.